New modular platform based on multi-adjuvanted amphiphilic chitosan nanoparticles for efficient lipopeptide vaccine delivery against group A streptococcus

Norpi, Abdin Shakirin Mohamad; Nordin, Muhammad Luqman; Ahmad, Nuraziemah; Katas, Haliza; Fuaad, Abdullah Al Hadi Ahmad; Sukri, Asif; Marasini, Nirmal; Azmi, Fazren

doi:10.1016/j.ajps.2022.04.002

Cited by 11 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this study, we selected a variety of known and previously examined immune-stimulating moieties (TMC, lipoPEI, DEAE-dextran) [ 22 , 26 , 32 ], as well as untested OTMC. Chitosan derivatives (e.g., TMC) are known immune stimulators [ 33 ], while lipidated sugars often demonstrate adjuvanting abilities, especially once incorporated into liposomes [ 34 , 35 , 36 , 37 , 38 ]. Therefore, we hypothesized that a lipidated analog of TMC (OTMC) may also be an effective immune stimulator.…”

Section: Discussionmentioning

confidence: 99%

The Development of Surface-Modified Liposomes as an Intranasal Delivery System for Group A Streptococcus Vaccines

et al. 2023

View full text Add to dashboard Cite

Intranasal vaccine administration can overcome the disadvantages of injectable vaccines and present greater efficiency for mass immunization. However, the development of intranasal vaccines is challenged by poor mucosal immunogenicity of antigens and the limited availability of mucosal adjuvants. Here, we examined a number of self-adjuvanting liposomal systems for intranasal delivery of lipopeptide vaccine against group A Streptococcus (GAS). Among them, two liposome formulations bearing lipidated cell-penetrating peptide KALA and a new lipidated chitosan derivative (oleoyl-quaternized chitosan, OTMC) stimulated high systemic antibody titers in outbred mice. The antibodies were fully functional and were able to kill GAS bacteria. Importantly, OTMC was far more effective at stimulating antibody production than the classical immune-stimulating trimethyl chitosan formulation. In a simple physical mixture, OTMC also enhanced the immune responses of the tested vaccine, without the need for a liposome delivery system. The adjuvanting capacity of OTMC was further confirmed by its ability to stimulate cytokine production by dendritic cells. Thus, we discovered a new immune stimulant with promising properties for mucosal vaccine development.

show abstract

Section: Discussionmentioning

confidence: 99%

The Development of Surface-Modified Liposomes as an Intranasal Delivery System for Group A Streptococcus Vaccines

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Indeed, several studies have demonstrated the potential use of chitosan NPs and derivatives as promising vehicles for vaccine delivery, due to the presence of numerous positive charges on its surface facilitating electrostatic interactions with the negative charges that characterize the sialic acid present in the mucus lining the epithelium [ 53 ]. The increased retention time of the loaded antigen [ 54 , 55 , 56 ] also makes antigen uptake possible [ 57 ] by promoting permeability relying on its ability to open tight junctions between epithelial cells [ 58 ]. It is possible to further increase the permeability and diffusion capacity of chitosan nanoparticles by chemically modifying them by adding short tails of poly(ethylene glycol), poly(2-hydroxyethyl acrylate), poly(2-ethyl-2-oxazoline) or poly(N-vinyl pyrrolidone) [ 59 ].…”

Section: Chitosan In Mucosal Vaccine Designmentioning

confidence: 99%

Efficiency of Chitosan Nanocarriers in Vaccinology for Mucosal Immunization

et al. 2023

View full text Add to dashboard Cite

The mucosal barrier constitutes a huge surface area, close to 40 m2 in humans, located mostly in the respiratory, gastrointestinal and urogenital tracts and ocular cavities. It plays a crucial role in tissue interactions with the microbiome, dietary antigens and other environmental materials. Effective vaccinations to achieve highly protective mucosal immunity are evolving strategies to counteract several serious diseases including tuberculosis, diphtheria, influenzae B, severe acute respiratory syndrome, Human Papilloma Virus infection and Acquired Immune Deficiency Syndrome. Interestingly, one of the reasons behind the rapid spread of severe acute respiratory syndrome coronavirus 2 variants has been the weakness of local immunization at the level of the respiratory mucosa. Mucosal vaccines can outperform parenteral vaccination as they specifically elicit protective mucosal immune responses blocking infection and transmission. In this scenario, chitosan-based nanovaccines are promising adjuvants-carrier systems that rely on the ability of chitosan to cross tight junctions and enhance particle uptake due to chitosan-specific mucoadhesive properties. Indeed, chitosan not only improves the adhesion of antigens to the mucosa promoting their absorption but also shows intrinsic immunostimulant abilities. Furthermore, by finely tuning the colloidal properties of chitosan, it can provide sustained antigen release to strongly activate the humoral defense. In the present review, we agnostically discuss the potential reasons why chitosan-based vaccine carriers, that efficiently elicit strong immune responses in experimental setups and in some pre-clinical/clinical studies, are still poorly considered for therapeutic formulations.

show abstract

“…The carriers can protect antigen proteins against rapid elimination and degradation during the administration process, improving the bioavailability and immunogenicity of antigen proteins and triggering a robust immune response. 11–13 To date, various carriers have been applied, including metal–organic frameworks, 14 inorganic nanoparticles, 15 polymers, 16,17 liposomes, 18,19 hydrogels, 20,21 and DNA nanostructures, 22 among which polymers with the advantages of easy modification and good stability are one of the most promising candidates. Recently, fluoropolymers such as fluorinated dendrimers and polyethyleneimines (PEI) have been widely applied as nucleic acid and protein delivery vectors.…”

Section: Introductionmentioning

confidence: 99%

A novel fluoropolymer as a protein delivery vector with robust adjuvant effect for cancer immunotherapy

Zhan,

He,

Huang

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

New modular platform based on multi-adjuvanted amphiphilic chitosan nanoparticles for efficient lipopeptide vaccine delivery against group A streptococcus

Cited by 11 publications

References 33 publications

The Development of Surface-Modified Liposomes as an Intranasal Delivery System for Group A Streptococcus Vaccines

The Development of Surface-Modified Liposomes as an Intranasal Delivery System for Group A Streptococcus Vaccines

Efficiency of Chitosan Nanocarriers in Vaccinology for Mucosal Immunization

A novel fluoropolymer as a protein delivery vector with robust adjuvant effect for cancer immunotherapy

Contact Info

Product

Resources

About